Back to Trades
Sell4
Travere Therapeutics, Inc.
TVTX
Total Value
$3.5M
Net $2.1M sold
Sales
$2.1M
4 transactions
Company Information
- Company Name
- Travere Therapeutics, Inc.
- Ticker Symbol
- TVTX
- CIK
- 0001438533
Insider Information
- Name
- REED ELIZABETH E
- Role
- Insider
- Location
- SAN DIEGO, CA
Filing Details
- Filing Date
- Apr 15, 2026
- Transaction Date
- Apr 13, 2026
- Accession Number
- 0001283303-26-000008
- Form Type
- 4
- Net Trading Amount
- -$2.1M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Apr 13, 2026 | Common Stock | 14,000 | — | Grant/Award | — |
| Apr 14, 2026 | Common Stock | 10,000 | $19.08 | Exercise | $190.8K |
| Apr 14, 2026 | Common Stock | 20,000 | $17.96 | Exercise | $359.2K |
| Apr 14, 2026 | Common Stock | 7,500 | $15.46 | Exercise | $116.0K |
| Apr 14, 2026 | Common Stock | 37,500 | $41.07 | Sale | $1.5M |
| Apr 14, 2026 | Common Stock | 7,215 | $41.93 | Sale | $302.5K |
| Apr 15, 2026 | Common Stock | 5,226 | $41.62 | Sale | $217.5K |
| Apr 15, 2026 | Common Stock | 1,559 | $42.53 | Sale | $66.3K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Apr 14, 2026 | Derivative | 7,500 | $15.46 | Exercise | $116.0K |
| Apr 14, 2026 | Derivative | 10,000 | $19.08 | Exercise | $190.8K |
| Apr 14, 2026 | Derivative | 20,000 | $17.96 | Exercise | $359.2K |
Footnotes
- (F1)On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.
- (F2)This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.
- (F3)Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
- (F4)This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
- (F5)The weighted average sale price for the transaction reported was $41.62, and the range of prices were between $41.255 and $42.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- (F6)The weighted average sale price for the transaction reported was $42.53, and the range of prices were between $42.335 and $42.66. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- (F7)The stock option is fully vested and exercisable.